Zevra Therapeutics, Inc.
ZVRA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001434647
In the last 90 days, Zevra Therapeutics, Inc. insiders filed 0 open-market purchases and 2 sales; 157 institutions reported holding it in 13F filings for Q2 2026, worth $642.0M in total; no superinvestor holds it.
Holders of 5% or more of ZVRA
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Zevra Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G/A | 7.60%4.08M shares | – | Feb 5, 20251 filing | Feb 5, 2025 | SEC |
| Woodline Partners LP | 13G/A | 6.20%3.48M shares | – | Nov 14, 20251 filing | Nov 14, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
7 Schedule 13D and 13G filings on Zevra Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Mar 27, 20262:15 PM ET | Vanguard Group Inc | 13G/A | 0.00%0 shares | –Below 5% | Mar 13, 2026 | SEC |
| Nov 14, 20254:15 PM ET | Woodline Partners LP | 13G/A | 6.20%3.48M shares | – | Sep 30, 2025 | SEC |
| Nov 13, 20259:01 AM ET | Adage Capital Management, L.P.and 2 others | 13G/A | 3.96%2.23M shares | −2.88 ppfrom 6.84%Below 5% | Sep 30, 2025 | SEC |
| Feb 14, 20254:32 PM ET | Nantahala Capital Management, LLCand 2 others | 13G/A | 4.38%2.34M shares | −1.18 ppfrom 5.56%Below 5% | Dec 31, 2024 | SEC |
| Feb 12, 20259:32 AM ET | Adage Capital Management, L.P.and 2 others | 13G | 6.84%3.65M shares | New | Dec 31, 2024 | SEC |
| Feb 5, 20251:23 PM ET | BlackRock, Inc. | 13G/A | 7.60%4.08M shares | – | Dec 31, 2024 | SEC |
| Nov 14, 20244:53 PM ET | Nantahala Capital Management, LLCand 2 others | 13G/A | 5.56%2.92M shares | – | Sep 30, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Zevra Therapeutics, Inc. shares.
No Form 144 notices for Zevra Therapeutics, Inc. are on file.